Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Jul;13(7):459-66.
doi: 10.1111/j.1751-7176.2011.00468.x. Epub 2011 Apr 22.

Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study

Steen Neldam  1 , Margreet Lang, Russell Jones; TEAMSTA-5 Investigators
Collaborators, Affiliations
Randomized Controlled Trial

Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study

Steen Neldam et al. J Clin Hypertens (Greenwich). 2011 Jul.

Abstract

An 8-week, randomized, double-blind, controlled study with single-pill combinations of telmisartan 40 mg or 80 mg/amlodipine 5 mg (T40/A5 or T80/A5) vs monotherapy with amlodipine 5 mg or 10 mg (A10) in 1097 patients with uncontrolled hypertension (diastolic blood pressure [BP] ≥ 90 mm Hg). T40/A5 and T80/A5 resulted in significantly greater (P<.0001) reductions in seated trough systolic/diastolic BP vs A5 (-7.4 mm Hg/-3.6 mm Hg; -8.8 mm Hg/-4.9 mm Hg) and a significantly greater (P<.001) proportion of patients achieving systolic/diastolic BP goal rate (60.0%/56.7%; 65.7%/63.8%) vs A5 (39.2%/42.0%). Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled T40-T80/A5; P<.0001). Switching patients with uncontrolled BP to a single-pill combination of T40/A5 or T80/A5 is a better treatment option than up-titration to full-dose monotherapy with A10.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition. A5 indicates amlodipine 5 mg; A10, amlodipine 10 mg; T40, telmisartan 40 mg; T80, telmisartan 80 mg.
Figure 2
Figure 2
Effect of 8 weeks of treatment with single‐pill combinations of telmisartan 40 mg/amlodipine 5 mg (T40/A5) or telmisartan 80 mg/amlodipine 5 mg (T80/A5) compared with monotherapy with A5 or amlodipine 10 mg (A10) on the change from baseline in seated trough systolic blood pressure (BP) (mm Hg) or diastolic BP (mm Hg).
Figure 3
Figure 3
Effect of 8 weeks of treatment with single‐pill combinations of telmisartan 40 mg/amlodipine 5 mg (T40/A5) or telmisartan 80 mg (T80)/A5 compared with monotherapy with A5 or amlodipine 10 mg (A10) on the proportion of patients who achieved blood pressure (BP) response (ie, systolic BP <140 mm Hg or systolic BP reduction ≥15 mm Hg; diastolic BP <90 mm Hg or diastolic BP reduction ≥10 mm Hg) (%).
Figure 4
Figure 4
Effect of 8 weeks of treatment with single‐pill combinations of telmisartan 40 mg/amlodipine 5 mg (T40/A5) or telmisartan 80 mg (T80)/A5 compared with monotherapy with A5 or amlodipine 10 mg (A10) on the proportion of patients with blood pressure (BP) goal (ie, systolic BP <140 mm Hg; diastolic BP <90 mm Hg; BP <140/90 mm Hg) (%).
Figure 5
Figure 5
Effect of 8 weeks of treatment with single‐pill combinations of telmisartan 40 mg/amlodipine 5 mg (T40/A5) or telmisartan 80 mg (T80)/A5 compared with monotherapy with A5 or amlodipine 10 mg (A10) on the proportion of patients on the rate of incidence of edema (%).
See this image and copyright information in PMC

References

    1. Mancia G, Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187. - PubMed
    1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572. - PubMed
    1. Dahlöf B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well‐being. LOA Study Group. J Hypertens. 1997;15:1327–1335. - PubMed
    1. Phillips RA, Kloner RA, Grimm RH Jr, et al. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich). 2003;5:17–23. - PMC - PubMed
    1. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich). 2006;8:634–641. - PMC - PubMed

Publication types

MeSH terms